{"disease":{"id":"relapsed-chronic-lymphocytic-leukemia","name":"relapsed chronic lymphocytic leukemia"},"drugs":{"marketed":[{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01589302","title":"PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Kami Maddocks, MD","has_results":true},{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT06547528","title":"A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00963105","title":"Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04872621","title":"Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05479994","title":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT03206918","title":"Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06644183","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Jennifer R. Brown, MD, PhD","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT05805605","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04305444","title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Zhejiang DTRM Biopharma","has_results":false},{"nct_id":"NCT03263637","title":"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04191187","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03708003","title":"Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT04624633","title":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"Jennifer R. Brown, MD, PhD","has_results":true},{"nct_id":"NCT03734198","title":"Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT04808570","title":"A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05963217","title":"Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04030195","title":"Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Precision BioSciences, Inc.","has_results":true},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT03624036","title":"Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05720052","title":"A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"MingSight Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04978779","title":"A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Vincerx Pharma, Inc.","has_results":false},{"nct_id":"NCT02181478","title":"Intra-Osseous Co-Transplant of UCB and hMSC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03739554","title":"CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Cyclacel Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03639324","title":"Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT04757259","title":"Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}